addressing a critical need to find cancer early and treat cancer specifically bioaffinity technologies, inc. develops tests and therapies to detect and treat cancer at the cellular level. our first product, cypath® flow cytometry for lung cancer (cypath® lung), has been licensed by precision pathology services for continued development and commercial sale as a laboratory developed test. cypath® lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures and lower patient anxiety and medical costs.
Company profile
Ticker
BIAF, BIAFW
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Syneos Health • Icon • Medpace • Incyte • Zymergen • OmniAb ...
SEC CIK
Corporate docs
Subsidiaries
OncoSelect® Therapeutics, LLC • Precision Pathology Laboratory Services, LLC ...
IRS number
465211056
BIAF stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
17 Apr 24
424B3
Prospectus supplement
16 Apr 24
ARS
2023 FY
Annual report to shareholders
15 Apr 24
DEFA14A
Additional proxy soliciting materials
15 Apr 24
DEF 14A
Definitive proxy
15 Apr 24
EFFECT
Notice of effectiveness
8 Apr 24
POS AM
Prospectus update (post-effective amendment)
5 Apr 24
S-1
IPO registration
4 Apr 24
PRE 14A
Preliminary proxy
2 Apr 24
POS AM
Prospectus update (post-effective amendment)
1 Apr 24
Transcripts
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.51 mm | 4.51 mm | 4.51 mm | 4.51 mm | 4.51 mm | 4.51 mm |
Cash burn (monthly) | 1.26 mm | 749.06 k | 764.83 k | 608.78 k | 11.67 k | 134.50 k |
Cash used (since last report) | 8.73 mm | 5.20 mm | 5.31 mm | 4.23 mm | 81.01 k | 933.93 k |
Cash remaining | -4.22 mm | -691.86 k | -801.41 k | 282.13 k | 4.43 mm | 3.58 mm |
Runway (months of cash) | -3.4 | -0.9 | -1.0 | 0.5 | 379.6 | 26.6 |
Institutional ownership, Q3 2023
6.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 11 |
Opened positions | 6 |
Closed positions | 4 |
Increased positions | 1 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 140.70 mm |
Total shares | 722.31 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Roby Joyce | 603.13 k | $1.01 mm |
Captrust Financial Advisors | 43.64 k | $50.79 mm |
Two Sigma Investments | 21.64 k | $25.19 mm |
Vanguard | 20.00 k | $23.28 mm |
STT State Street | 17.60 k | $21.47 mm |
Creative Planning | 12.10 k | $14.08 mm |
Tower Research Capital | 4.05 k | $4.71 mm |
UBS UBS Group AG - Registered Shares | 65.00 | $76.00 k |
WFC Wells Fargo & Co. | 38.00 | $44.00 k |
Qube Research & Technologies | 38.00 | $46.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Apr 24 | Maria Zannes | Common Stock | Payment of exercise | Dispose F | No | No | 2.65 | 28,264 | 74.90 k | 201,242 |
8 Apr 24 | Maria Zannes | Common Stock | Option exercise | Acquire M | No | No | 1.16 | 64,848 | 75.22 k | 229,506 |
8 Apr 24 | Maria Zannes | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.16 | 64,848 | 75.22 k | 0 |
4 Apr 24 | Timothy P Zannes | Common Stock | Payment of exercise | Dispose F | No | No | 2.58 | 29,031 | 74.90 k | 46,124 |
4 Apr 24 | Timothy P Zannes | Common Stock | Option exercise | Acquire M | No | No | 1.16 | 64,848 | 75.22 k | 75,155 |
4 Apr 24 | Timothy P Zannes | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.16 | 64,848 | 75.22 k | 0 |
3 Apr 24 | Steven Girgenti | Common Stock | Payment of exercise | Dispose F | No | No | 2.24 | 33,438 | 74.90 k | 1,023,168 |
3 Apr 24 | Steven Girgenti | Common Stock | Option exercise | Acquire M | No | No | 1.16 | 64,848 | 75.22 k | 1,056,606 |
3 Apr 24 | Steven Girgenti | Stock Option Common Stock | Option exercise | Dispose M | No | No | 1.16 | 64,848 | 75.22 k | 0 |
26 Feb 24 | Robert A. Anderson | Common Stock | Option exercise | Acquire M | No | No | 1.155 | 64,848 | 74.90 k | 121,856 |
News
12 Health Care Stocks Moving In Friday's Intraday Session
5 Apr 24
bioAffinity Technologies Q4 EPS $(0.26) Up From $(0.44) YoY, Sales $2.21M Down From $2.35M YoY
2 Apr 24
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
11 Mar 24
12 Health Care Stocks Moving In Monday's Intraday Session
11 Mar 24
Nasdaq Gains 100 Points; Campbell Soup Earnings Top Views
6 Mar 24
Press releases
bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth
24 Apr 24
bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening
9 Apr 24
bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results
1 Apr 24
Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement
8 Mar 24
bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement
8 Mar 24